| Name | Title | Contact Details |
|---|
Northern Michigan Regional Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Northern Michigan Regional Hospital is based in Petoskey, MI. You can find more information on Northern Michigan Regional Hospital at www.northernhealth.org
Pain Management Service is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The University of Vermont Medical Center is part of a six-hospital network serving patients and their families in Vermont and northern New York. We`re not just caregivers and staff - we`re your friends and neighbors, offering expertise, kind words and compassionate care when and where you need them. We are dedicated to providing you with the best medical care possible. The University of Vermont Medical Center, along with the Robert Larner M.D. College of Medicine The University of Vermont and College of Nursing and Health Sciences, is one of 138 academic medical centers in the country. Through The University of Vermont Health Network and collaborative relationships throughout Vermont and northern New York, we are able to provide the highest quality care, informed by academic research, to patients throughout our region. The UVM Medical Center, along with its three founding organizations, The University of Vermont College of Medicine and College of Nursing and Health Sciences, share a rich history dating back to the 1800s. The UVM Medical Center is committed to the development of an Integrated Delivery System which provides high value health care to the communities we serve and enhances our academic mission. Our mission is to improve the health of the people in the communities we serve by integrating patient care, education, and research in a caring environment.
Specialty Medical Sales is a Lewisville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.